logo
Twitter
Discord
Email
logo
Electromed, Inc.

Electromed, Inc.

AMEX•ELMD
CEO: Mr. James L. Cunniff
Sector: Healthcare
Industry: Medical - Devices
Listing Date: 2010-08-13
Electromed, Inc. develops, manufactures, markets, and sells airway clearance therapy and related products that apply high frequency chest wall oscillation (HFCWO) therapy in pulmonary care for patients of various ages in the United States and internationally. The company offers SmartVest airway clearance system for patients with compromised pulmonary functions, including bronchiectasis and cystic fibrosis, as well as neuromuscular conditions, such as cerebral palsy and amyotrophic lateral sclerosis; SmartVest SQL System; SmartVest Clearway System that consists of an inflatable therapy garment, a programmable air pulse generator, and a patented single-hose that delivers air pulses from the generator to the garment to create oscillatory pressure on the chest wall; and SmartVest Connect, a wireless technology that allows data connection between physicians and patients to track therapy performance and collaborate in treatment decisions. It also provides single patient use SmartVest and SmartVest Wrap products for health care providers in the acute care setting. The company offers its products to hospitals, home health care centers, pulmonary rehabilitation centers, cystic fibrosis centers, neuromuscular clinics, and other clinics through distributors. It markets its products to physicians, health care providers, and directly to patients. Electromed, Inc. was incorporated in 1992 and is headquartered in New Prague, Minnesota.
Contact Information
500 Sixth Avenue NW, New Prague, MN, 56071, United States
952-758-9299
smartvest.com
Market Cap
$232.12M
P/E (TTM)
28.3
4.1
Dividend Yield
--
52W High
$35.56
52W Low
$17.73
52W Range
57%
Rank24Top 10.8%
5.7
F-Score
Modified Piotroski Analysis
Based on 10-year fundamentals
Average • 5.7 / 9 points
Scoring Range (0-9)
8-9: Excellent Value
6-7: Strong Fundamentals
4-5: Average Quality
0-3: Weak Performance
Data Period: 2016-2025

Financial Dashboard

Q1 2026 Data

Revenue

$16.89M+15.13%
4-Quarter Trend

EPS

$0.26+52.94%
4-Quarter Trend

FCF

-$98.00K-104.31%
4-Quarter Trend

2026 Q1 Earnings Highlights

Key Highlights

Revenue Growth Strong Net revenues totaled $16.89M USD for the quarter, increasing 15.1% compared to prior period.
Net Income Surges 44.9% Net income reached $2.14M USD, driven by increased revenue and gross profit performance.
Hospital Sales Accelerate Hospital revenue grew substantially by 51.7% to $1.05M USD due to increased sales focus.
Basic EPS Improvement Basic earnings per share increased to $0.26 USD from $0.17 USD in the prior year period.

Risk Factors

Operating Cash Flow Decline Net cash provided by operating activities fell significantly to $169K USD from $2.31M USD.
Working Capital Shifts Large $2.35M decrease in accrued compensation negatively impacted cash provided by operations.
Inventory Investment Inventories increased by $515K USD during the quarter, consuming operational cash resources.
Credit Facility Maturity Revolving line of credit for $2.5M USD is set to expire in December 2025, requiring renewal.

Outlook

Liquidity Forecast Positive Working capital of $35.8M USD and available credit expected to meet liquidity needs for twelve months.
Share Repurchase Activity Company utilized $1.00M USD to repurchase common stock under the recently approved authorization.
SG&A Expense Increase SG&A expenses rose 9.6% due to higher sales headcount and ongoing compensation benchmarking efforts.
Tax Legislation Evaluation Evaluating impact of OBBBA legislation regarding deductibility of U.S.-based research expenditures.

Peer Comparison

Revenue (TTM)

Accuray IncorporatedARAY
$450.90M
+1.5%
Inogen, Inc.INGN
$347.03M
+4.7%
Health Catalyst, Inc.HCAT
$316.06M
+4.6%

Gross Margin (Latest Quarter)

MaxCyte, Inc.MXCT
92.4%
+16.1pp
CVRx, Inc.CVRX
86.8%
+3.6pp
Sight Sciences, Inc.SGHT
86.4%
+2.5pp

Key Metrics

Symbol
Market Cap
P/E (TTM)
ROE (TTM)
Debt to Assets
SGHT$342.08M-7.3-61.6%35.0%
PROF$248.26M-6.3-86.8%0.7%
ELMD$232.12M28.318.7%0.2%

Long-Term Trends

Last 4 Quarters
Revenue
Net Income
Operating Cash Flow
4Q Revenue CAGR
1.3%
Moderate Growth
4Q Net Income CAGR
2.8%
Profitability Slowly Improving
Cash Flow Stability
100%
Strong Cash Flow

Research & Insights

Next earnings:Feb 10, 2026
|
EPS:$0.27
|
Revenue:$18.05M
Reports
All Years
  • Form 10-Q - Q1 2026

    Period End: Sep 30, 2025|Filed: Nov 12, 2025|
    Revenue: $16.89M+15.1%
    |
    EPS: $0.26+52.9%
    Beat
  • Form 10-K - FY 2025

    Period End: Jun 30, 2025|Filed: Aug 26, 2025|
    Revenue: $64.00M+17.0%
    |
    EPS: $0.90+50.0%
    Beat
  • Form 10-Q - Q3 2025

    Period End: Mar 31, 2025|Filed: May 13, 2025|
    Revenue: $15.68M+13.1%
    |
    EPS: $0.22+29.4%
    Beat
  • Form 10-Q - Q2 2025

    Period End: Dec 31, 2024|Filed: Feb 11, 2025|
    Revenue: $16.26M+18.7%
    |
    EPS: $0.23+15.0%
    Beat
  • Form 10-Q - Q1 2025

    Period End: Sep 30, 2024|Filed: Nov 12, 2024|
    Revenue: $14.67M+19.0%
    |
    EPS: $0.17+834.1%
    Beat
  • Form 10-K - FY 2024

    Period End: Jun 30, 2024|Filed: Aug 27, 2024|
    Revenue: $54.72M+13.8%
    |
    EPS: $0.60+62.2%
    Beat
  • Form 10-Q - Q3 2024

    Period End: Mar 31, 2024|Filed: May 7, 2024|
    Revenue: $13.87M+14.9%
    |
    EPS: $0.17+30.8%
    Beat
  • Form 10-Q - Q2 2024

    Period End: Dec 31, 2023|Filed: Feb 13, 2024|
    Revenue: $13.69M+16.7%
    |
    EPS: $0.20+66.7%
    Beat